Tags: Cancer | pancreatic | cancer | drug | trial | success

Pancreatic Cancer Drug Succeeds in Mid-Stage Study

Pancreatic Cancer Drug Succeeds in Mid-Stage Study

(Copyright Fotolia)

Friday, 06 January 2017 08:36 AM

Halozyme Therapeutics Inc said its lead drug to treat a late form of pancreated cancer met the main goal in a mid-stage study, sending its shares soaring in premarket trading.

The study population showed a statistically significant increase in progression-free survival, the company said.

Pancreatic cancer is the third-leading cause of cancer-related death in the United States.

Halozyme's shares were up 44 percent at $15.40 in trading before the opening bell on Thursday.

© 2019 Thomson/Reuters. All rights reserved.

   
1Like our page
2Share
Health-News
Halozyme Therapeutics Inc said its lead drug to treat a late form of pancreated cancer met the main goal in a mid-stage study, sending its shares soaring in premarket trading.The study population showed a statistically significant increase in progression-free survival, the...
pancreatic, cancer, drug, trial, success
73
2017-36-06
Friday, 06 January 2017 08:36 AM
Newsmax Media, Inc.
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved